Compare DCGO & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DCGO | ELOX |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Managed Health Care | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.7M | 43.8M |
| IPO Year | 2020 | N/A |
| Metric | DCGO | ELOX |
|---|---|---|
| Price | $0.60 | $11.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $2.38 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 48.2K |
| Earning Date | 05-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $322,196,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.45 | $10.00 |
| 52 Week High | $1.78 | $15.00 |
| Indicator | DCGO | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 57.74 | 38.06 |
| Support Level | $0.47 | N/A |
| Resistance Level | $0.65 | $15.00 |
| Average True Range (ATR) | 0.05 | 2.29 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 91.21 | 27.50 |
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company uses its care delivery platform to provide mobile health services, virtual care management, and ambulance services. It has two reporting segments: Mobile Health Services and Transportation Services. A majority of its revenue is generated from the Mobile Health Services segment, which includes various healthcare services performed at homes, offices, and other locations and event services such as on-site healthcare support at sporting events and concerts. Geographically, the company generates a majority of its revenue from the United States and the rest from the United Kingdom.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.